Results 181 to 190 of about 19,558 (200)
Studies on Phospholipids in the Action of a Lupus Coagulation Inhibitor
Pathology, 1975 Plasma from a patient with early manifestations of disseminated lupus erythematosus, a prolonged partial thromboplastin time with kaolin, mildly prolonged prothrombin time, and a circulating inhibitor affecting the assay of several clotting factors was investigated.
Thomas Exner +2 more
openalex +4 more sources
The lupus coagulation inhibitor and venous thrombosis: a report of four cases
Clinical & Laboratory Haematology, 1980 Hywel Williams, R. Laurent, T. Gibson
openalex +4 more sources
British Journal of Haematology, 1996 An acquired IgG inhibitor to factor XIII was identified in a 30‐year‐old Vietnamese woman with systemic lupus erythematosus. The IgG fraction was isolated from plasma by chromatography on an agarose gel column and by protein G adsorption. The anti‐factor XIII activity, identified within the IgG fraction, inhibited factor XIII from both normal plasma ...
Ferhaan Ahmad +4 more
openalex +4 more sources
Blood, 2006 Abstract The cell surface glycoproteins thrombomodulin (TM) and endothelial protein C receptor (EPCR) are major intermediaries in the down-regulation of thrombin and are noted to be shed from endothelial cells (ECs) due to the actions of proinflammatory cytokines, thrombin and other agents.
Yale S. Arkel +4 more
openalex +3 more sources
Circulating inhibitors of blood coagulation associated with procainamide‐induced lupus erythematosus
American Journal of Hematology, 1978 AbstractWe studied a patient being treated with procainamide in whom we observed a high antinuclear antibody titer and prolonged activated partial thromboplastin (PTT), prothrombin (PT), and Stypven times (ST). Serum antibody concentrations against single‐stranded DNA were elevated while those against native DNA were not elevated, suggesting the ...
Stephen Davis +3 more
openalex +4 more sources
Reumatología Clínica (English Edition), 2008 Hematologic signs of systemic lupus erythematosus are diverse (SLE). Although a delayed coagulation time is anti-phospholipid antibody related, thrombotic events are the usual clinical manifestation. Spontaneous appearance of circulating anticoagulant in the absence of a previous coagulation disorder is secondary to the development of antibodies to ...
Enrique Ortiz Jiménez +2 more
openalex +4 more sources
A Circulating Lupus-like Coagulation Inhibitor Induced by Chlorpromazine
Journal of Clinical Psychopharmacology, 1984 A variety of immune phenomena have been associated with chlorpromazine. One such factor, the lupus-like anticoagulant, while nonspecific, has been reported in 26 to 75% of chronic chlorpromazine recipients, although the exact incidence is unknown and requires further investigation.
Gary D. Tollefson +2 more
openalex +4 more sources
Natural inhibitors of blood coagulation and fibrinolysis in patients with lupus anticoagulant
Blood Coagulation & Fibrinolysis, 1992 We studied the natural inhibitors (NI) of blood coagulation and fibrinolysis in 50 patients with lupus anticoagulant (LA), in order to identify possible alterations of these NI, that could favour thrombotic manifestations. We found no statistically significant difference in antithrombin III, protein C and alpha 2-antiplasmin between controls and ...
L Kordich +4 more
openalex +4 more sources
LUPUS-TYPE COAGULATION INHIBITOR IN HAIRY CELL LEUKAEMIA AND REOSOLUTION WITH SPLENECTOMY
British Journal of Haematology, 1987 A. S. Duncombe +2 more
openalex +3 more sources